Valdecoxib : the rise and fall of a COX-2 inhibitor. - Wikidata - wikimedia - TriplyDB

Valdecoxib : the rise and fall of a COX-2 inhibitor.

Valdecoxib : the rise and fall of a COX-2 inhibitor.

http://www.wikidata.org/entity/Q38091707

about

Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke Expression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer Chiral Derivatives of Xanthones: Investigation of the Effect of Enantioselectivity on Inhibition of Cyclooxygenases (COX-1 and COX-2) and Binding Interaction with Human Serum Albumin.Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa.Celecoxib for the treatment of atherosclerosis.Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain.Update on the use of cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs in horses In silico and In vitro evaluation of the anti-inflammatory potential of Centratherum punctatum Cass-A.Lowering side effects of NSAID usage in osteoarthritis: recent attempts at minimizing dosage.A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly.Comparison of NSAIDs activity in COX-2 expressing and non-expressing 2D and 3D pancreatic cancer cell cultures.

P2860

Q24193086-945B133F-7B23-4128-9CDD-DF21C718EF7B Q28271874-A912B825-5889-477C-BE38-666BB11A3878 Q33801546-2C551283-7BC9-454F-AFF5-F9580FBB3AD4 Q33851532-A4813ECC-63AD-4B22-9D79-99DACB6B8A46 Q38364542-C3D116CD-5F68-40D5-9D68-1C1E92D4A804 Q38759585-BBF687CA-B057-4EF1-970F-0A233129995A Q39007494-8D267015-76F2-4303-AB3D-00F6A4BFA227 Q41584889-E2353118-3337-4D46-8B02-0ACBBB8FC395 Q48060946-D2F1B109-19D0-4BCC-B967-8F2E1BCC5D2B Q48166311-D269D1BB-9B13-41E9-B988-7F0CA5B33EBE Q49385576-0E80790A-6CF9-404F-B895-222D5A47C15D Q55379173-89342B20-4620-41C2-A3AE-AC4B63CCA456

P2860

Valdecoxib : the rise and fall of a COX-2 inhibitor.

http://www.wikidata.org/entity/Q38091707

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Valdecoxib : the rise and fall of a COX-2 inhibitor.

@en

type

label

Valdecoxib : the rise and fall of a COX-2 inhibitor.

@en

prefLabel

Valdecoxib : the rise and fall of a COX-2 inhibitor.

@en

P1433

Q38091707-AFD43C25-4819-43ED-AE28-724BDC4B9B37

P1476

Q38091707-EEAFE066-A8BE-4D9D-8021-E884E9E1EFE7

P2093

Q38091707-9698C384-0586-492F-8B8E-412F8238A196

P2860

Q38091707-04F1BDE0-5D89-4F01-AB5A-9CC98FE6CCD4

Q38091707-072CCBAE-93AD-415F-9529-66869E0644B5

Q38091707-0B86AA88-D322-4C8A-A97F-68D4B3DF697A

Q38091707-0C7D4B6E-8D56-405F-BB60-4F1BA7977890

Q38091707-1540144B-E594-4EC8-8CAB-C38F4DA67DFF

Q38091707-1F3EDEC2-90FE-43F0-BE83-969AFB89A57D

Q38091707-214BB3BB-5CA5-4891-B309-BA4CDEFF80CB

Q38091707-232BCF99-BDC5-42CE-85DC-F8F72251A8B1

Q38091707-2AD83DB5-2E40-4905-AD65-DEAF5D601A20

Q38091707-2FC230BE-866A-4ADF-B884-00C8E0C171DC

P304

Q38091707-F000F92B-CC46-40BF-8640-702D046DA95F

P31

Q38091707-A8971CFA-CF30-4F3F-9292-371785D9560E

P356

Q38091707-233E1724-D53E-42BF-8620-9127F7995EA9

P407

Q38091707-6964452E-4567-4BA7-99DE-C53B2C38E783

P433

Q38091707-30D29AE4-B992-4A3F-A699-1EBD7F8AB562

P478

Q38091707-48616CC8-2C8E-46E6-9D67-4C4050C14B42

P50

Q38091707-C727523C-77F4-4DB0-B972-5B0B00CC10AF

P577

Q38091707-7CB589DD-527E-4113-B6C1-56964B048C63

P698

Q38091707-4C89CE75-9BD9-4B6A-82B6-F90CE8D00A86

P356

14656566.2013.783568

P1433

Expert Opinion on Pharmacotherapy

P1476

Valdecoxib : the rise and fall of a COX-2 inhibitor.

@en

P2093

Inoshi Atukorala

http://www.w3.org/2001/XMLSchema#string

P2860

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

Aspirin resistance after coronary artery bypass grafting

Role of prostacyclin in the cardiovascular response to thromboxane A2

Aspirin and mortality from coronary bypass surgery

De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin

Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial

Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery

Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthrit

Celecoxib for the prevention of sporadic colorectal adenomas

P304

1077-1086

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2013.783568

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

David J. Hunter

P577

2013-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23517091

http://www.w3.org/2001/XMLSchema#string